Company Analysis
SkinBioTherapeutics: Analysing Implied 750k Zenakine Royalties
SkinBioTherapeutics has not explicitly disclosed a £750k Zenakine royalty figure in its FY25 accounts, with commercial terms remaining confidential. However, the CEO has publicly acknowledged that straightforward arithmetic using figures in the annual report allows this amount to be inferred as attributable to Zenakine royalties. At first glance, a number
